Le Lézard
Classified in: Health
Subject: SVY

PharmaFocus: Visual Analysis of Immuno-Oncology Development and Opportunities



NEW YORK, Oct. 6, 2017 /PRNewswire/ -- PharmaFocus: Visual Analysis of Immuno-Oncology Development and Opportunities

Summary

Read the full report: https://www.reportlinker.com/p05134501


Immuno-Oncology (IO) is uniquely positioned to become the fifth pillar of cancer treatment alongside surgery, radiotherapy, chemotherapy, and other targeted treatments. In order to assist our clients with navigating the burgeoning amount information arising as a result of the rapidly growing field of IO clinical research, GlobalData is offering a comprehensive analysis of both pipeline and marketed active immunity IO therapies.

Scope
Key Topics Covered -
- Immune Checkpoint Modulators - Trends in Clinical Trial Development
- Competitive Assessment of Marketed PD-(L)1 Checkpoint Modulators
- Emergence of New Immune Checkpoint Targets
- Clinical and Commercial Opportunities for Highly Anticipated CAR Cell Therapies
- Cell Vaccines: Steady Development Stimulated by Prior IO Success
- Promising IO-IO Combinations Utilizing Oncolytic Viruses

Reasons to buy
- The PharmaFocus consists of a highly-visual slide deck that is intended to facilitate the dissemination of aggregated data and insights from analyses of over 800 IO products that are either marketed or in Phase I-III of clinical development.
- Types of graphical analyses include - Cumulative Plots, Aggregated Bubble Plots, Pie Charts, Matrix Analyses
- Unique, actionable insights applicable to IO drugs in five major categories: Immune Checkpoint Modulators, Cellular Immunotherapies, Oncolytic Viruses, Peptide Vaccines, and Bispecific T-Cell Engagers are provided in this report.
- Analysis of over 4000 clinical trials enrolling patients with 18 solid tumors and eight hematological cancers are included.

Read the full report: https://www.reportlinker.com/p05134501

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

https://www.reportlinker.com


__________________________
Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker


These press releases may also interest you

at 00:15
HUNTINGTON BEACH, Calif., Oct. 21, 2017 /PRNewswire/ -- Wavelengths Recovery was a proud sponsor of "Chasing the Dragon - Opioid Awareness Community Event" held on Oct. 18. This event was held at the City National Grove of Anaheim. Many members of...

20 oct 2017
VANCOUVER, Oct. 20, 2017 /CNW/ - The Honourable Ginette Petitpas Taylor, Federal Minister of Health, will announce additional support for the BC Centre of Excellence for Women's Health through Health Canada's Substance Use and Addictions Program to...

20 oct 2017
Product photos are available at http://bit.ly/2hSM8qr OTTAWA, Oct. 20, 2017 /CNW/ - Hen Long Oriental Gifts and Foods Co. Ltd. is recalling Captain's Choice brand Frozen Shrimp Shaomai from the marketplace because it contains egg which is not...

20 oct 2017
CAMBRIDGE, Mass., Oct. 20, 2017 /PRNewswire/ -- Clowd Foundry LLC announces "cardio at your desk" using its Rocket Rower XSQ platform. Studies show that getting physical movement throughout the day is critical to our health. Sitting and even stand-up...

20 oct 2017
EDMONTON, Oct. 20, 2017 /CNW/ - Today, federal, provincial and territorial (FPT) Ministers responsible for health concluded their meeting in Edmonton, Alberta.  Ministers held productive discussions on a number of health-related priorities,...

20 oct 2017
LONDON, Oct. 20, 2017 /PRNewswire/ -- GlaxoSmithKline plc [LSE/NYSE: GSK] today announced that the US Food and Drug Administration (FDA) has approved Shingrix (Zoster Vaccine Recombinant, Adjuvanted) for the prevention of shingles (herpes zoster) in...




News published on 6 october 2017 at 11:12 and distributed by: